t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.
A patient with t(9;22)-positive chronic myelogenous leukemia (CML) developed a resistance to therapy with imatinib mesylate (Glivec) which coincided with the appearance of t(5;6;12) in the same cells with t(9;22) [46,XX,t(5;6;12)(q14?;q21?;q23?),t(9;22)(q34;q11)]. She remains in a continuous chronic phase of CML. This is the first reported instance of karyotype evolution temporally associated, and possibly involved, with the induction of resistance to imatinib mesylate but without any signs of evolution of leukemia toward a more anaplastic and aggressive form.
Denčić-Fekete
Marija
M
Clinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia. mdencicfekete@yahoo.com.
Đorđević
Vesna
V
Clinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Storlazzi
Clelia Tiziana
CT
Department of Genetics and Microbiology, University of Bari, Bari, Italy.
Janković
Gradimir
G
Clinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Bogdanović
Andrija
A
Clinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Jovanović
Jelica
J
Clinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.
Rocchi
Mariano
M
Department of Genetics and Microbiology, University of Bari, Bari, Italy.
Todorić-Živanović
Biljana
B
Military Medical Academy, 11000, Belgrade, Serbia.
Strnad
Milica
M
Military Medical Academy, 11000, Belgrade, Serbia.
Gotić
Mirjana
M
Clinical Center Serbia, Institute of Hematology, Koste Todorovića 2 Street, 11000, Belgrade, Serbia.